Innovent Biologics (HKG:1801) recorded a profit of 813.6 million yuan in the year 2025, compared with a loss of 94.6 million yuan a year prior, according to a Thursday Hong Kong bourse filing.
Earnings per share stood at 0.47 yuan for the period, compared with a loss per share of 0.06 yuan in the previous fiscal year.
The drug company's revenue from contracts with customers rose 38% to 13 billion yuan from 9.42 billion yuan previously.
The firm said the turnaround to profit was driven by significant economies of scale from strong revenue growth and improved operating efficiency.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments